Takeda flashes red light on 'breakthrough' narcolepsy drug after PhII trials turned up mysterious safety signal
Takeda is bringing two Phase II narcolepsy trials to a premature end in the aftermath of a “safety signal.”
The trials tested TAK-994 as a treatment for both type 1 and type 2 narcolepsy. It’s one of multiple oral orexin agonists that the pharma giant has been developing to target the chronic sleep-wake disorder.
Investigators have stopped dosing patients as a precautionary measure, the company said, without disclosing what exactly went wrong. The current priority is on “timely interpretation of the benefit/risk profile of TAK-994 and to determine next steps for the program.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,300+ biopharma pros reading Endpoints daily — and it's free.